The Valley Desk

ArticleSkin health and diseasePublished

Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Skin health and disease
Published
PubMed ID
42540023
PubMed Central ID
PMC13425078
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal